The abstract is read at the publisher; the summary is JClub's.
A single intravenous dose of T-IDLE STCE in a murine Sjögren's syndrome-associated dry eye model induces deep, time-limited depletion of plasmablasts and plasma cells.
- Why it matters: Targeted BCMA×CD3 T cell engager therapy is limited by ex vivo manufacturing and systemic delivery, restricting its use in autoimmune disorders like autoantibody-driven dry eye.
- What they did: The study used an integration-deficient lentiviral vector to program endogenous T cells to secrete BCMA×CD3 TCEs in vivo, then assessed immune effects and safety in mice and cynomolgus monkeys.
- The result: The treatment reversed lacrimal gland inflammation and restored tear production in mice, showed plasma cell clearance with a favorable safety profile in monkeys, and redirected nearby non-activated T cells toward BCMA-expressing targets.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.